Stockscreener 앱 받기
84.08
0.55%
0.67
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $112 - Moomoo
Spyre Therapeutics (SYRE) Reveals Promising Results from SKYLINE Trial - GuruFocus
Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating - marketscreener.com
Spyre reports positive phase 2 trial results for UC drug By Investing.com - Investing.com South Africa
Spyre reports positive phase 2 trial results for UC drug - Investing.com UK
Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - The Manila Times
Spyre Therapeutics posts positive Phase 2 SKYLINE Part A results for SPY002, RHI -10.7 (p - TradingView
Spyre Therapeutics (NASDAQ: SYRE) posts positive Phase 2 SPY002 ulcerative colitis data - Stock Titan
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Certain Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
SYRE completes enrollment in SKYWAY basket study on SPY072, stock up - MSN
Spyre Therapeutics stock hits 52-week high at 79.75 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 79.75 USD - Investing.com
Capital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Spyre Therapeutics grants inducement awards to four employees - scanx.trade
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Part of Equity Inducement Awards - Quiver Quantitative
Arrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYRE - MarketBeat
SYRE Maintains Buy Rating by Deutsche Bank -- Price Target Raised to $115 - GuruFocus
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - sharewise.com
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $115 From $102, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Deutsche Bank raises Spyre stock price target on competitor setback By Investing.com - Investing.com South Africa
Deutsche Bank raises Spyre stock price target on competitor setback - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock By Investing.com - Investing.com South Africa
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock - Investing.com UK
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock - Investing.com
Spyre Therapeutics (SYRE) CEO Turtle sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
6.83%
0.89%
자본화:
|
볼륨(24시간):